Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01843205 · ClinicalTrials.gov registry record · Phase 1
Buspirone as a Candidate Medication for Methamphetamine Abuse
A Phase 1 study of Methamphetamine-dependence and Methamphetamine Abuse, sponsored by University of Kentucky.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01843205 is a Phase 1 study of Methamphetamine-dependence and Methamphetamine Abuse that has completed, run by University of Kentucky. The registered enrollment target is 9 participants, below the 106-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01843205, a Phase 1 study of Methamphetamine-dependence and Methamphetamine Abuse, has completed, sponsored by University of Kentucky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Methamphetamine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce methamphetamine use, however, these interventions are not universally effective and treatment effects diminish over time. Development of a pharmacotherapy that enhances the efficacy of these interventions is a priority for the National Institute on Drug Abuse. This study proposes to determine the impact of buspirone maintenance on self-administration of methamphetamine. These preliminary data will be used to support further research developing buspirone as a pharmacotherapy for methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate the reinforcing effects of methamphetamine.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methamphetamine
Study Locations (1)
Kentucky
- University of Kentucky Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01843205
The ClinicalTrials.gov registry entry for NCT01843205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (92% lower). The listed sponsor is University of Kentucky, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Methamphetamine-dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01843205 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT01843205 about?
NCT01843205 is a clinical study titled "Buspirone as a Candidate Medication for Methamphetamine Abuse". Methamphetamine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce methamphetamine use, however, these interventions are not universally effective and treatment effects diminish over time. Development of a pharmacother...
What is the current status of trial NCT01843205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-04. Estimated completion is 2017-03.
What conditions does trial NCT01843205 study?
This clinical trial studies the following conditions: Methamphetamine-dependence, Methamphetamine Abuse.
What interventions are being tested in trial NCT01843205?
The interventions under investigation include: Placebo (DRUG), Methamphetamine (DRUG).
Who is sponsoring clinical trial NCT01843205?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01843205 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine-dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety Interaction Trial Ibudilast and Methamphetamine
COMPLETED · Phase 1
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
RECRUITING · Phase 3
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
rTMS for Craving in Methamphetamine Use Disorder
RECRUITING · NA
-
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.